These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32471486)

  • 1. Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation.
    Zilkova M; Nolle A; Kovacech B; Kontsekova E; Weisova P; Filipcik P; Skrabana R; Prcina M; Hromadka T; Cehlar O; Rolkova GP; Maderova D; Novak M; Zilka N; Hoozemans JJM
    Acta Neuropathol Commun; 2020 May; 8(1):74. PubMed ID: 32471486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans.
    Weisová P; Cehlár O; Škrabana R; Žilková M; Filipčík P; Kováčech B; Prčina M; Wojčiaková Ľ; Fialová Ľ; Smolek T; Kontseková E; Žilka N; Novák M
    Acta Neuropathol Commun; 2019 Aug; 7(1):129. PubMed ID: 31391090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake.
    Funk KE; Mirbaha H; Jiang H; Holtzman DM; Diamond MI
    J Biol Chem; 2015 Aug; 290(35):21652-62. PubMed ID: 26126828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.
    Kontsekova E; Zilka N; Kovacech B; Skrabana R; Novak M
    Alzheimers Res Ther; 2014; 6(4):45. PubMed ID: 25478018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody.
    Luo W; Liu W; Hu X; Hanna M; Caravaca A; Paul SM
    Sci Rep; 2015 Jun; 5():11161. PubMed ID: 26057852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy.
    Congdon EE; Chukwu JE; Shamir DB; Deng J; Ujla D; Sait HBR; Neubert TA; Kong XP; Sigurdsson EM
    EBioMedicine; 2019 Apr; 42():157-173. PubMed ID: 30910484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.
    Novak P; Schmidt R; Kontsekova E; Kovacech B; Smolek T; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Zilka N; Winblad B; Novak M
    Alzheimers Res Ther; 2018 Oct; 10(1):108. PubMed ID: 30355322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau antibody isotype induces differential effects following passive immunisation of tau transgenic mice.
    Bajracharya R; Brici D; Bodea LG; Janowicz PW; Götz J; Nisbet RM
    Acta Neuropathol Commun; 2021 Mar; 9(1):42. PubMed ID: 33712083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcγ-receptor binding and functional lysosomes.
    Andersson CR; Falsig J; Stavenhagen JB; Christensen S; Kartberg F; Rosenqvist N; Finsen B; Pedersen JT
    Sci Rep; 2019 Mar; 9(1):4658. PubMed ID: 30874605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency.
    Agadjanyan MG; Zagorski K; Petrushina I; Davtyan H; Kazarian K; Antonenko M; Davis J; Bon C; Blurton-Jones M; Cribbs DH; Ghochikyan A
    Mol Neurodegener; 2017 May; 12(1):33. PubMed ID: 28472993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease.
    Hopp SC; Lin Y; Oakley D; Roe AD; DeVos SL; Hanlon D; Hyman BT
    J Neuroinflammation; 2018 Sep; 15(1):269. PubMed ID: 30227881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.
    Kontsekova E; Zilka N; Kovacech B; Novak P; Novak M
    Alzheimers Res Ther; 2014; 6(4):44. PubMed ID: 25478017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Novak P; Schmidt R; Kontsekova E; Zilka N; Kovacech B; Skrabana R; Vince-Kazmerova Z; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Winblad B; Novak M
    Lancet Neurol; 2017 Feb; 16(2):123-134. PubMed ID: 27955995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice.
    Jiang T; Zhang YD; Chen Q; Gao Q; Zhu XC; Zhou JS; Shi JQ; Lu H; Tan L; Yu JT
    Neuropharmacology; 2016 Jun; 105():196-206. PubMed ID: 26802771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia.
    De Marco D; Taggenbrock R; Crespo R; Koudstaal W; Ramsburg E; Apetri A
    J Vis Exp; 2018 Nov; (141):. PubMed ID: 30474638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement.
    Lee SH; Le Pichon CE; Adolfsson O; Gafner V; Pihlgren M; Lin H; Solanoy H; Brendza R; Ngu H; Foreman O; Chan R; Ernst JA; DiCara D; Hotzel I; Srinivasan K; Hansen DV; Atwal J; Lu Y; Bumbaca D; Pfeifer A; Watts RJ; Muhs A; Scearce-Levie K; Ayalon G
    Cell Rep; 2016 Aug; 16(6):1690-1700. PubMed ID: 27475227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development.
    Novak P; Zilka N; Zilkova M; Kovacech B; Skrabana R; Ondrus M; Fialova L; Kontsekova E; Otto M; Novak M
    J Prev Alzheimers Dis; 2019; 6(1):63-69. PubMed ID: 30569088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model.
    Shi Y; Manis M; Long J; Wang K; Sullivan PM; Remolina Serrano J; Hoyle R; Holtzman DM
    J Exp Med; 2019 Nov; 216(11):2546-2561. PubMed ID: 31601677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology.
    Joly-Amado A; Davtyan H; Serraneau K; Jules P; Zitnyar A; Pressman E; Zagorski K; Antonyan T; Hovakimyan A; Paek HJ; Gordon MN; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A; Morgan D
    Neurobiol Dis; 2020 Feb; 134():104636. PubMed ID: 31629891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders.
    Kayed R; Jackson GR
    Curr Opin Immunol; 2009 Jun; 21(3):359-63. PubMed ID: 19482462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.